Digital Health

Esplanade HealthTech Ventures is a venture capital firm focused on digital health. Based in Toronto, with offices in Montreal, the fund invests globally and actively partners with early-stage and high growth digital health companies shaping the future of healthcare delivery. Esplanade has deep entrepreneurial, investment, and industry experience and provides its portfolio company founders with privileged access to the firm's partners, experts, and broader global ecosystem.

Primarily focused on Seed / Series A digital health and life sciences software opportunities with an interesting AI component

Biotech

The Fonds de Solidarité FTQ is a Quebec labour sponsored fund. We invest in many different sectors, one of which is life sciences, in which we have invested more than 2B$ over the last 30 years.

We can only invest in companies that are based in Quebec. We mainly invest in biotech but are open to discussing with companies in other sectors

Biotech

For over 25 years, Genesys Capital has been investing at the leading edge of medical innovation and has a proven track record of identifying emerging bioscience opportunities and transforming them into commercially successful companies.

We're interested in biopharma, biotechnology, diagnostic, and medical device start-ups. Our first entry point is typically Seed or Series A. Our interest is in leading or co-leading.

MedTech

We are a Canadian physician & dentist exclusive angel investment group that advises, connects, and invests in disruptive healthcare ventures.

1. Incorporated in Canada
2. Product is clinically relevant and prototype- or MVP-ready
3. You are:
a. Seeking pre-seed, seed, or intermediate financing
b. Open to investments from non-syndicated, individual physician/dentist members with
minimum cheque sizes of $25,000
c. Valued at =< $20M CAD pre-money
4. You have a lead investor and/or have secured at least 50% of the total raise

Digital Health

Humber River Health (HRH) is a leading integrated health system that serves a diverse population of over 400,000 patients per year in Northwest Toronto. HRH is comprised of a 722-bed acute centre at our Wilson site, which is North America’s first fully digital hospital, in addition to the Schulich Centre for Family Medicine, the HRH Research Institute, Reactivation Care Centres (RCC) at both our Finch and Church Campuses, and the Humber Meadows Long-Term Care Home on our Finch site. HRH is recognized globally for leveraging technology to deliver high-reliability care. New innovations are adopted throughout our hospital including our digital Command Centre, which HRH was the first to adopt in Canada. HRH also has a robust robotic surgery program, being the first to acquire the da Vinci surgical robot and more recently acquiring the MAKO robotic system. In addition to over 20 research studies per year in the health services & population health fields, HRH has participated in over 20 clinical trial studies in areas including oncology, nephrology, anesthesia, bariatrics, infectious diseases and orthopedics.

-Innovative Healthcare company that is able to leverage clinical data
-Seeking clinical partner for research or trials
-Developing AI to improve healthcare processes and clinical flow

MedTech

iGan Partners invests in breakthrough healthcare technologies—primarily medical devices, diagnostics, and AI-enabled healthcare infrastructure—that improve clinical outcomes while reducing the cost of care. The firm focuses on companies at the intersection of clinically validated innovation and scalable commercialization, partnering early with founders to support regulatory strategy, clinical adoption, and strategic exits to global healthcare leaders.

We are not looking for biotech or pharma companies.

Digital Health

Investments & Advisory Services

Digital Health

MedTech

Venture Capital Investors with a singular focus on the Medtech Sector.

Medtech

Other

We shorten the path to capital by helping founders accelerate their investor readiness and connect with aligned capital.

Must be passed ideation.

MedTech

INOVAIT is Canada’s image-guided therapy (IGT) and artificial intelligence (AI) network. As a pan-Canadian network, INOVAIT supports companies and academic institutions from coast to coast to commercialize cutting-edge medical technologies that positively impact the healthcare system and create high-quality jobs. The network brings together companies, research institutes, post-secondary institutions, and not-for-profit organizations to collaborate on game-changing projects to transform healthcare. INOVAIT strengthens the Canadian medtech ecosystem by fuelling continuous innovation that revolutionizes healthcare. INOVAIT was established in 2020 by Sunnybrook Research Institute and supported by the Government of Canada’s Strategic Response Fund.

- image-guided therapy
- medical imaging
- artificial intelligence
- machine learning
- big data applications

Biotech

Investissement Québec is a Québec government corporation whose mission is to actively contribute to economic development by stimulating business growth, innovation, productivity, and sustainable development. Acting as a strategic investor, lender, and financial partner, Investissement Québec supports Québec-based companies across all stages of development, with a particular focus on high-growth sectors, including life sciences and health technologies.

Target companies typically meet the following criteria:
- Clear value proposition supported by differentiated technology, products, or services
- Strong management team with relevant industry and execution experience
- Meaningful traction (e.g. revenues, contracts, partnerships, regulatory progress, or clinical validation, where applicable)
- Willingness to engage in a long-term partnership with an institutional investor

Pharma

Invest Ontario is the partner for businesses seeking strategic growth in Ontario – one of the world’s top investment destinations.
As the province’s dedicated investment attraction agency, we serve as businesses’ one-window access to the best of what Ontario has to offer.

growth stage

Pharma

Developing Dual use Biodefence technology

co-development, Licensing to Global

Biotech

J.P. Morgan focus on solutions for life sciences companies at all stages—from startups to established businesses, pre-clinical through commercialization. We have decades of experience in the sector and understand the complex financial and regulatory challenges life sciences companies face. We bring a wealth of expertise and insights to the venture capital space, and we’re ready to help you stay positioned for innovation and growth.

Biotech, medtech, specialty pharma, CRO, CDMO, generics, diagnostics

MedTech

Leva Capital is an early-stage venture fund investing in MedTech and Digital Health companies that improve patient outcomes, expand access to care, and support human longevity. We back capital-efficient teams with a clear path to regulatory approval and commercialization, often leveraging Canada's talent base and innovation ecosystem to scale globally. Through Fund I, Leva has invested in 22 early-stage companies, primarily at the seed stage, with 18 based in Canada. We are currently raising Fund II and plan to continue supporting the Canadian ecosystem.

Pre-seed to series A-stage Medtech, Digital Health, Biotech, Diagnostics companies.

Biotech

Linearis with its tandem Ventures Fund and Laboratory, is pioneering and supporting discoveries to prevent, detect, and cure diseases through direct investments in innovative AI-powered life sciences companies (Seed to Series B).

AI-powered life sciences companies (BioPharma, MedTech, Diagnostics, Digital Health)
Stage: Seed to Series B

Biotech

Life sciences venture capital firm

Biotech or medtech companies

Biotech

At Mission BioCapital, we provide early-stage capital to the next generation of awesome life science entrepreneurs and the platform where they can realize their visions. This approach has revolutionized the way life science start-ups progress from idea to key data through a model that champions collaboration at the center of everything we do. Our team has a deep-rooted commitment to empowering exceptional life science entrepreneurs from all walks of life. Founded in 2009, we are now investing out of our fifth fund. From your first experiment in our shared lab space through to the clinic, we want to be your partner in accelerating development of scientific solutions – faster, focused and more efficiently – to individuals and communities in most need.

Private biotech companies developing therapeutics that are raising Seed, Series A, or Series B financing rounds.

Biotech

MPM BioImpact combines the 30+ year track record of the MPM CAPITAL® services and offerings in biotech venture capital with BioImpact’s dedication to impact and 10+ years of experience in public investing. Together, we manage over $3 billion AUM across early-stage venture funds, private/public impact funds and a public equities fund.

Not sure yet

Other

Life science venture development and investment company

Life science companies